InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,427.13
(
-2.31%
)
US TECH 100
18,480.00
(
-0.30%
)
Dow Jones
39,853.87
(
0.00%
)
Brent Oil
79.59
(
-1.42%
)
Bitcoin
64,236.46
(
-1.74%
)
Post# of 1645
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

BottomBounce

Send PM Follow Ignore
Followers 898
Posts 149082
Boards Moderated 0
Alias Born 08/13/2010

BottomBounce

Re: bladerunner1717 post# 1497

Friday, 05/14/2021 6:01:06 AM

Friday, May 14, 2021 6:01:06 AM

Post# of 1645
$IBIO IBIO-201, the Company’s vaccine candidate combining antigens derived from the spike protein (“S protein”) fused with iBio’s patented LicKM™ booster molecule, recently completed IND-enabling toxicology studies. The studies identified no adverse effects at low or high doses.

“Combined with data from previous immune-response studies, these pathology results help demonstrate the potential value of LicKM as a useful tool in our vaccine development toolbox,” said Tom Isett, Chairman and CEO of iBio.

https://ir.ibioinc.com/news-events/press-releases/detail/157/ibio-reports-successful-covid-19-vaccine-toxicology-study

Nothing I say, post, or do should ever be considered financial advice. I may be holding a long, short or no position. I am NOT or NEVER have I been compensated to post on here or anywhere and all my posts are for entertainment purposes only.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up